‘Highjack’ Autoimmunity to Enhance Efficacy of Immunotherapy?

TrialsiteN

Bryant Furlow of Cancer Network reports on recent research published in Cell Systems and suggests that “tumors can be rendered susceptible by ‘hijacking’ immune cell recruitment signals through molecular master regulators” noted Angela M. Christiano, PhD, of the Herbert Irvine Comprehensive Cancer Center, Columbia University Medical Center, New York.

As quoted the Columbia researchers:  “[W]e propose a strategy for enhancing cancer immunotherapy that entails ‘hijacking’ the molecular mechanisms that activate the immune system in autoimmune disease and using them to essentially ‘tag’ evasive tumors for immune-mediated destruction. We reasoned that the molecular processes that encourage active immune cell infiltration to the target organs in autoimmune disease could be used to restore immune targeting against cancer cells.”

Angela M. Christiano profile

Herbert Irvine Comprehensive Cancer Center, Columbia University Medical Center,  Department of Genetics and Development

View article here